Publications
Dr. Peng's Research and Studies Published in Medical Journals: (from 2016 till now )
https://orcid.org/0000-0002-5829-6217
Antiepileptic drug optimization using ambulatory electrocorticographic data from an implanted brain‐responsive neurostimulator
Clinical Case Reports
2020-01-30 | journal-article
https://doi.org/10.1002/ccr3.2689
SREAT presenting as decades of intractable seizures and isolated delusional episodes with clinical, laboratory and EEG-confirmation of treatment response
SAGE Open Medical Case Reports
2019-05 | journal-article
Gastrointestinal Beriberi and Wernicke’s Encephalopathy Triggered by One Session of Heavy Drinking
Case Reports in Neurology
2019-04-18 | journal-article
Part of ISSN: 1662-680X
Reversible hand tremors, downbeat nystagmus, and an unsteady gait with nontoxic lithium level
Clinical Case Reports
2019-01-24 | journal-article
DOI: 10.1002/ccr3.1981
PMID: 30899510
Small-cell lung carcinoma and acute onset of antiglial nuclear antibody-positive limbic encephalitis
Clinical Case Reports
2017-03-08 | journal-article
DOI: 10.1002/ccr3.894
PMID: 28396782
Reversible dementia: subclinical seizure in early-onset dementia
Clinical Case Reports
2017-02-06 | journal-article
DOI: 10.1002/ccr3.843
PMID: 28265399
Hashimoto's encephalopathy - presenting with epilepsia partialis continua and a frontal lobe lesion
Clinical Case Reports
2017 | journal-article
PMID: 29375853
Correlations of Clusters of Non-Convulsive Seizure and Magnetic Resonance Imaging in a Case With GAD65-Positive Autoimmune Limbic Encephalitis
Journal of Clinical Medicine Research
2016 | journal-article
PMID: 27429684
Peggie Smith's Publications and Research
Elizabeth Zauber, Peggie A. Smith and Leo Verhagen (2011), Fundamentals of Deep Brain Stimulation Programming in William J. Marks, Jr. (Ed.), Deep Brain Stimulation Management (pp. 43-56). Cambridge University Press
ACT Study: Botox Purified Neurotoxin Complex as Headache Prophylaxis in Adolescents (Children 12 to <18 years of age) with Chronic Migraine. Protocol No.: 191622-103. Sub-Investigator
ALD403-006 PROMISE STUDY: Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Frequent Episodic Migraines. Protocol No.:ALD403-CLIN-00., Sub-Investigator
Amgen 334 20120295 A double blind placebo controlled trial to evaluate the safety and efficacy of AMG334 in chronic Migraine Prevention. Protocol No.: AMG334 20120295. Sub-Investigator
APEX Study: Multicenter, Randomized, Active-Controlled Efficacy and Safety Study Comparing Extended Duration Betrixaban with Standard of Care Enoxaparin for the Prevention of Venous Thromboembolism in Acute Medically Ill Patients. Protocol Number 11-019. Sub-Investigator and Study Coordinator
Ceregene: A Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 Adeno-Associated Virus Serotype 2 [AAV2] - Neurturin in Subjects with Idiopathic Parkinson’s Disease. Protocol No. CERE 120 and CERE 120-09. Study Coordinator
The CHAMP Study: Amitriptyline and Topiramate in the Prevention of Childhood Migraine. IND #112,220; Sub-Investigator and Study
DALF-PS-1016: Double-Blind, Placebo-Controlled, parallel-Group Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke (MILESTONE). Protocol No.: DALF-PS-1016. Sub-Investigator
GMA-US-NEU-0206: FORWARD Study: A multicenter, proscpective, randomized, open-label study to compare the efficacy, safety, and tolerability of BOTOX and Topiramate for Headache Prophylaxis in Adults with Chronic Migraine. Protocol No.: GMA-US-NEU-0206. Sub-Investigator
PRISMS: Phase IIIb, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients with Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits. Protocol Number: ML29093. Sub-Investigator and Study Coordinator
RESPECT-ESUS: Randomized, double-blind, evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate (110mg or 150 mg oral BID) versus acetylsalicylic acid (100mg oral q.d.) in patients with embolic stroke of undetermined source. Protocol No. 1160.189. Sub-Investigator
Spheramine: Study of the Safety, Tolerability and Efficacy of Spheramine Implanted Bilaterally into the Postcommissural Putamen of Patients with Advanced Parkinson’s Disease. Study Coordinator